7 Hills Pharma has successfully dosed the first patient in a Phase 1b/2a clinical trial of Alintegimod, a first-in-class integrin-targeted agonist aimed at overcoming aPD-1-resistant solid tumors. This novel approach enhances T cell activation and immune cell trafficking, offering new hope for patients with difficult-to-treat cancers. Supported by CPRIT and the National Cancer Institute, this trial marks a significant advancement in cancer immunotherapy.

7 Hills Pharma has been awarded a $4.7 million CPRIT grant to advance 7HP935, a first-in-class small molecule gene therapy that enhances hematopoietic stem cell transplantation (HSCT). This therapy aims to improve stem cell engraftment and reduce infection risks, offering a better treatment option for cancer and genetic disorder patients, especially those from ethnic minorities with limited stem cell donor matches.

7 Hills Pharma has received a $13.5 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to advance 7HP349 (Alintegimod) into a Phase 1b/2a trial targeting PD-1-resistant solid tumors. This funding supports the development of a novel immunotherapy to overcome immune checkpoint inhibitor resistance, offering hope for checkpoint blockade-resistant patients.

7 Hills Pharma receives a $3 million SBIR grant from the National Institute of Allergy and Infectious Diseases (NIAID) to develop the first vaccine for Chagas disease. This innovative vaccine combination with 7HP349 aims to protect millions from the Trypanosoma cruzi parasite and prevent severe outcomes of the disease.

7 Hills Pharma announces the expansion of its patent portfolio with new claims covering innovative integrin agonist combination therapies. The newly issued patent no. 11,311,619 strengthens 7HP’s leadership in leveraging integrin activation to overcome immunotherapy resistance, expanding applications across diverse therapeutic areas.

7 Hills Pharma, in collaboration with MD Anderson and Texas Heart Institute, published a groundbreaking study in The Journal of Clinical Investigation showcasing how 7HP349 can convert "cold" melanoma tumors into "hot," T cell-enriched tumors, enhancing the efficacy of immune checkpoint blockade therapies. This novel approach offers a promising step forward in cancer immunotherapy.

7 Hills Pharma announces that 7HP349, its lead oral immunostimulant, has been granted FDA Fast Track designation for use in combination with a CTLA-4 inhibitor for the treatment of anti-PD-1-resistant metastatic melanoma. This designation offers an expedited path for the development of 7HP349 in overcoming immunotherapy resistance in melanoma and other cancers.

7 Hills Pharma announces the successful completion of a Phase I clinical trial for 7HP349, an oral immunostimulant that enhances immuno-oncology drugs, COVID-19, and influenza vaccines. The study demonstrated excellent safety, tolerability, and pharmacokinetics, paving the way for Phase II clinical trials in solid tumors and vaccination for immunocompromised populations.

Researchers from the Texas Heart Institute, UTMB, and 7 Hills Pharma have pioneered a groundbreaking study on the use of 7HP349, an oral integrin activator, as a vaccine adjuvant. This research, published in Nature Partner Journal Vaccines, shows how 7HP349 enhances immune responses, with promising applications for Chagas disease and COVID-19 vaccines, particularly in immunocompromised individuals.

7 Hills Pharma appoints Michael S. Perry, CEO of AVITA Medical, as its first Chairman of the Board of Managers. The company is advancing small molecule integrin activators, including 7HP349, to enhance immuno-oncology drugs and vaccines for COVID-19, influenza, and cancer treatments.

7 Hills Pharma is developing 7HP349, a novel immune activator to enhance the effectiveness of COVID-19 and influenza vaccines as well as cancer immunotherapies. This proprietary compound activates integrins, improving cell adhesion and immune responses, and aims to address age-related immune deficiencies, ultimately improving treatment outcomes for vulnerable populations.

In this guest commentary, Upendra Marathi and Joseph Bailes propose two key incentives to boost drug repositioning for COVID-19: restoring BARDA funding and extending market exclusivity for repurposed drugs, offering critical support for expanding the pipeline of treatments for COVID-19.

7 Hills Pharma announces the first healthy volunteers dosed in its Phase 1 trial of 7HP349, an immunostimulant aimed to enhance immuno-oncology drugs and COVID-19 & influenza vaccines, improving immune responses and increasing effectiveness in older adults.

7 Hills Pharma receives a $2M SBIR grant from the National Cancer Institute (NCI) to support Phase 1 trials of 7HP349, a small molecule designed to enhance immuno-oncology drugs and vaccines for COVID-19 and flu.

7 Hills Pharma secures broad USPTO patent protection for its integrin activators, positioning the company as a key partner for immuno-oncology and COVID-19 vaccine developers. FDA-approved IND trials set to begin soon.

7 Hills Pharma announces positive preclinical data on 7HP349, an oral immunostimulant that enhances COVID-19 vaccine effectiveness by boosting IgG antibody responses and accelerating immune protection. Learn how this integrin activator could improve vaccine efficacy, particularly for older adults.

Discover how 7 Hills Pharma’s integrin activators enhance immunotherapies by boosting cell adhesion, improving COVID-19 vaccines, checkpoint inhibitors, and cancer treatments. Learn more from BIO Digital 2020.

7 Hills Pharma’s integrin platform technology enhances immunotherapies, boosting COVID-19 vaccine efficacy and checkpoint inhibitors by improving cell adhesion for stronger immune responses. Learn more from BIO Digital 2020.

7 Hills Pharma launches a COVID-19 vaccine program targeting at-risk elderly, leveraging integrin activator technology to enhance immune responses and improve vaccine effectiveness. Learn more about this breakthrough approach.

7 Hills Pharma appoints Dr. Lionel D. Lewis as Chief Medical Officer, bringing extensive immuno-oncology expertise to advance 7HP349 integrin activator for solid tumor treatment. Learn more about this leadership addition.